Myeloproliferative Neoplasm, BCR-ABL1 Negative

molecular subtype

Identifier: CI-CAN-00003386
Entity page: /cancer/myeloproliferative-neoplasm-bcr-abl1-negative ↗
Edges: 435

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Myeloproliferative Neoplasm, BCR-ABL1 Negative approved for …APPROVED_FORderived4 of 4
← approved for	Ruxolitinibsmall molecule FDA (US) · approved · 2026-05-01 · polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.	—	approved	Polycythemia Vera	1	Regulatory	openfda	graph →
← approved for	Ropeginterferon Alfa-2b

Myeloproliferative Neoplasm, BCR-ABL1 Negative investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 98show all (up to 200)
→ investigated in trials for	Ruxolitinibsmall molecule 43 trials (17 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 31 trials (4 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 24 trials (6 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 12 trials (2 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Ropeginterferon Alfa-2bother 12 trials (8 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Azacitidinesmall molecule 8 trials (2 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 8 trials (2 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Pacritinibsmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Hydroxyureasmall molecule 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Aspirinsmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Sirolimussmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Decitabinesmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Fedratinibsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinib Mesylatesmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Myeloproliferative Neoplasm, BCR-ABL1 Negative	4	Observed	clinicaltrials	graph →

Myeloproliferative Neoplasm, BCR-ABL1 Negative investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 98show all (up to 200)

→ investigated in trials for

Ruxolitinibsmall molecule

43 trials (17 active) · roll-up of the cancer and its descendants

—

Myeloproliferative Neoplasm, BCR-ABL1 Negative

Observed

Myeloproliferative Neoplasm, BCR-ABL1 Negative studied in …STUDIED_INderived10 of 333show all (up to 200)
→ studied in	NCT06661915Phase 2 · recruiting A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · condition mapped ONTOLOGY_EXACT · 333 trials mapped (110 active)	—	—	Essential Thrombocythemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03560752Phase 1 · active not recruiting CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant · condition mapped ALIAS · 333 trials mapped (110 active)	—	—	Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT05025488Phase 1 · active not recruiting Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm · condition mapped ALIAS · 333 trials mapped (110 active)	—	—	Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07722611Phase 2/Phase 3 · recruiting A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) · condition mapped ONTOLOGY_EXACT · 333 trials mapped (110 active)	—	—	Polycythemia Vera	1	Observed	clinicaltrials	graph →
→ studied in	NCT05548062active not recruiting Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera · condition mapped ONTOLOGY_EXACT · 333 trials mapped (110 active)	—	—	Polycythemia Vera	1	Observed	clinicaltrials	graph →
→ studied in	NCT06398457early Phase 1 · recruiting Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies · condition mapped ALIAS · 333 trials mapped (110 active)	—	—	Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07839858completed A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France · condition mapped ONTOLOGY_EXACT · 333 trials mapped (110 active)	—	—	Polycythemia Vera	1	Observed	clinicaltrials	graph →
→ studied in	NCT05320198Phase 1/Phase 2 · recruiting Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia · condition mapped ALIAS · 333 trials mapped (110 active)	—	—	Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT02530034Phase 1 · active not recruiting Hu8F4 in Treating Patients With Advanced Hematologic Malignancies · condition mapped ALIAS · 333 trials mapped (110 active)	—	—	Primary Myelofibrosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07469891Phase 1 · recruiting A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms · condition mapped ONTOLOGY_EXACT · 333 trials mapped (110 active)	—	—	Polycythemia Vera	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains